Results 231 to 240 of about 29,210 (297)

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial. [PDF]

Blood Adv
Niemann CU, Dubois J, Nasserinejad K, da Cunha-Bang C, Kersting S, Enggaard L, Veldhuis GJ, Mous R, Mellink CHM, van der Kevie-Kersemaekers AF, Dobber JA, Poulsen CB, Razawy W, Hollestein R, Frederiksen H, Janssens A, Schjødt I, Dompeling EC, Ranti J, Brieghel C, Mattsson M, Bellido M, Tran HTT, Kater AP, Levin MD.   +24 more
europepmc   +1 more source

Zanubrutinib as Upfront Treatment in de Novo B-Cell Prolymphocytic Leukemia: The Case of Two Elderly Patients. [PDF]

Mediterr J Hematol Infect Dis
Giorgi S, Leonardi G, Maccaferri M, Sbadili E, Caterina C, Fera G, Paolini A, Potenza L, Candoni A, Luppi M, Marasca R.   +10 more
europepmc   +1 more source

Efficacy, Toxicity and Effect of Pretreatment Cardiologic Consultation on Outcomes of Ibrutinib Therapy for Chronic Lymphocytic Leukemia-A KroHem Study. [PDF]

Cancers (Basel)
Mandac Smoljanović I, Aurer I, Bulj N, Dreta B, Miljak A, Petričević F, Ivić M, Bašić-Kinda S, Zatezalo V, Madunić S, Čaržavec D, Sinčić-Petričević J, Grohovac D, Jakšić O, Krečak I, Morić-Perić M, Coha B, Berneš P, Živković N, Pejša V.   +19 more
europepmc   +1 more source

Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLL. [PDF]

Blood Adv
Allan JN, Ran T, Ding Z, He J, Bokun A, Qureshi ZP, O'Brien SM.   +6 more
europepmc   +1 more source

Pharmacogenetic Biomarkers of Ibrutinib Response and Toxicity in Chronic Lymphocytic Leukemia: Insights from an Observational Study. [PDF]

Pharmaceuticals (Basel)
Pérez-Gómez N, Sanz-Solas A, Cuevas B, Cuevas MV, Alonso-Madrigal C, Loscertales J, Álvarez-Nuño R, García C, Zubiaur P, Villapalos-García G, Parra-Garcés RM, Mejía-Abril G, Alcaraz R, Vinuesa R, Díaz-Gálvez FJ, González-Oter M, García-Sancha N, Azibeiro-Melchor R, González-López TJ, Abad-Santos F, Labrador J, Saiz-Rodríguez M.   +21 more
europepmc   +1 more source

Elucidating novel immune profiles for predicting infection in high-risk cohorts: a pilot study in patients with relapsed and refractory chronic lymphocytic leukaemia. [PDF]

Clin Transl Immunology
Williams LJ, Li-Wai-Suen CS, Garnham AL, Bader SM, Tam CS, Whitechurch A, Slavin MA, Doerflinger M, Teh BW.   +8 more
europepmc   +1 more source

Ganciclovir-resistant CMV encephalitis in a mantle cell lymphoma patient on pirtobrutinib: Case report. [PDF]

IDCases
Unterborn R, Brade K, Bair SM, Chiu CY.
europepmc   +1 more source

Cost impact of Bruton's tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia. [PDF]

J Comp Eff Res
Kittai AS, Patel DA, Shafrin J, Zawadzki N, Shetty VS, Barqawi YK, Rhodes JM.   +6 more
europepmc   +1 more source

Correction: Ibrutinib as treatment for Bing-Neel syndrome reclassified as glioblastoma: a case report. [PDF]

J Med Case Rep
Gravesen CD, Chanchiri I, Kristensen IB, Jensen MB, Harbo FSG, Dahlrot RH.   +5 more
europepmc   +1 more source

Inhibition of head and neck squamous cell carcinoma by Bruton's tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells. [PDF]

Cancer Immunol Immunother
Bopp AR, Lamenza FF, Upadhaya P, Ryan NM, Kazmierowicz N, Jordanides PP, Siddiqui A, Pracha SH, Roth P, Iwenofu OH, Oghumu S.   +10 more
europepmc   +1 more source